News & Updates
Filter by Specialty:
Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023
byAudrey Abella
In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.
Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023Osemitamab plus CAPOX proven safe, prolongs survival in advanced G/GEJ cancer
15 Nov 2023
byStephen Padilla
First-line treatment with TST001 (osemitamab) in combination with capecitabine and oxaliplatin (CAPOX) is safe and well tolerated in patients with advanced gastric/gastroesophageal junction (G/GEJ) cancer, according to a study presented at ESMO 2023.